A Comparison of Elderly Patients with Aggressive Histology Lymphoma who Were Entered or Not Entered on to a Randomized Phase II Trial

References

• Shipp M. A., Harrington D. P., Anderson J. R. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Greiner T. C., Medeiros L. J., Jaffe E. S. Non-Hodgkin's lymphoma. Cancer 1995; 75: 370–380
   PubMed Web of Science ®Google Scholar
• Fisher R. I., Gaynor E. R., Dahlberg S. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Meyer R. M., Quirt I. C., Skillings J. R. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 1770–1776
   PubMed Web of Science ®Google Scholar
• Longo D. L., DeVita V. T., Duffey P. L. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 1991; 9: 25–38
   PubMed Web of Science ®Google Scholar
• Benson A. B., III, Preger J. P., Bean J. A. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol 1991; 9: 2067–2075
   PubMed Web of Science ®Google Scholar
• Egorin M. J. Cancer pharmacology in the elderly. Semin Oncol 1993; 20: 43–49
   PubMed Web of Science ®Google Scholar
• Kimmick G. G., Fleming R., Muss H. B. Cancer chemotherapy in older adults. A tolerability perspective. Drugs Aging 1997; 10: 34–49
   PubMed Web of Science ®Google Scholar
• Dixon D. O., Neilan B., Jones S. E. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma. The Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295–305
   PubMed Web of Science ®Google Scholar
• O'Reilly S. E., Klimo P., Connors J. M. Low-dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J. Clin Oncol 1991; 9: 741–747
   PubMed Web of Science ®Google Scholar
• McMaster M. L., Johnson D. H., Greer J. P. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma. Cancer 1991; 67: 1487–1492
   PubMed Web of Science ®Google Scholar
• Zagonel V., Tirelli U., Carbone A. Combination chemotherapy specifically devised for elderly patients with unfavorable non-Hodgkin's lymphoma. Cancer Invest 1991; 8: 577–582
   Web of Science ®Google Scholar
• Meyer R. M., Gyger M., Langley R. A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma. Leuk Lymph 1998; 30: 591–600
   PubMed Web of Science ®Google Scholar
• Gomez H., Mas L., Casanova L. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998; 16: 2352–2358
   PubMed Web of Science ®Google Scholar
• Sonneveld P., De Ridder M., Van der Lelie H. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13: 2530–2539
   PubMed Web of Science ®Google Scholar
• McKelvey E. M., Gottlieb J. A., Wilson H. E. Hydroxyldaunorubicin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Bastion Y., Blay J.-Y., Divine M. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival - a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol 1997; 15: 2945–2953
   PubMed Web of Science ®Google Scholar
• Tirelli U, Errante D., Van Glabbeke M. CHOP is the standard regimen in patients 370 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 27–34
   PubMed Web of Science ®Google Scholar
• Meyer R., Browman G. P., Samosh M. L. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 2386–2393
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Berard C. W., Brown B. W., Jr. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Carbone P. P., Kaplan H. S., Musshoff K. Report of the Committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Oken M. M., Creech R. H., Tormcy D C. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• Pagano M., Halvorsen K. T. An algorithm for finding the exact significance levels of r(times)c contingency tables. J Am Stat Assoc 1981; 79: 931–934
   Google Scholar
• Mood A., Graybill F., Boies D. Introduction to the theory of statistics. McGraw-Hill, New York 1963
   Google Scholar
• Fleiss J. L. Statistical methods for rates and proportions. Wiley, New York 1973
   Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958; 53: 457–481
   Web of Science ®Google Scholar
• Peto R., Peto J. Asymptomatically efficient rank invariant test procedures. J R Stat Soc A 1972; 135: 185–206
   Web of Science ®Google Scholar
• De Lena M., Maiello E., Lorusso V. Comparison of CHOP-B vs CEOP-B in poor prognosis' non-Hodgkin's lymphomas. A randomized trial. Medical Oncol Tumor Pharmacother 1989; 6: 163–169
   PubMedGoogle Scholar
• Chao N. J., Rosenberg S. A., Horning S. J. CEPP -an effective and well-tolerated regimen in poor risk aggressive non-Hodgkin's lymphoma. Blood 1990; 76: 1293–1298
   PubMed Web of Science ®Google Scholar
• Bagley C. M.J., DeVita V. T.J., Berard C. W. Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine and prednisone. Ann Int Med 1972; 76: 227–234
   PubMed Web of Science ®Google Scholar
• Lamy P. P. Modifying drug dosage in elderly patients. Current Geriatric Therapy, T. R. Covington, J. I. J. Walker. WB Saunders Company, Philadelphia 1984; 35–72
   Google Scholar
• Repetto L., Vercelli M., Simoni C. Comorbidity among elderly patients with and without cancer. J Clin Oncol 1994; 13: 467a
   Google Scholar
• Armitage J. O., Potter J. F. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. J Am Geriatr Soc 1984; 32: 269–273
   PubMed Web of Science ®Google Scholar
• Vose J. M., Armitage J. O., Weisenburger D. D. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838–1844
   PubMed Web of Science ®Google Scholar
• Coiffier B., Gisselbrecht C., Herbrecht R. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989; 7: 1018–1026
   PubMed Web of Science ®Google Scholar
• Hoskins P. J., Ng V., Spinelli J. J. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 1991; 9: 220–226
   PubMed Web of Science ®Google Scholar
• Gomez H., Hidalgo M., Casanova L. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol 1998; 16: 2065–2069
   PubMed Web of Science ®Google Scholar
• Shipp M. A. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has “high-risk” disease. Blood 1994; 5: 1165–1173
   Google Scholar
• Chatta G. S., Dale D. C. Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors. Drugs Aging 1996; 9: 37–47
   PubMed Web of Science ®Google Scholar
• Begg C. B., Carbone P. P. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 1983; 52: 1986–1992
   PubMed Web of Science ®Google Scholar
• Martin J. F., Henderson W. G., Zacharski L. R. Accrual of patients into a multihospital cancer clinical trial and its implications on planning future studies. Am J Clin Oncol 1984; 7: 173–182
   PubMed Web of Science ®Google Scholar
• Tirelli U., Zagonel V., Serraino D. Non-Hodgkin's lymphomas in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer Lymphoma Group study. J Clin Oncol 1988; 6: 1708–1713
   PubMed Web of Science ®Google Scholar
• Newcomb P. A., Carbone P. P. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 1993; 85: 1580–1584
   PubMed Web of Science ®Google Scholar